COMMUNIQUÉS West-GlobeNewswire

Auris Medical Provides Board of Directors Update
26/09/2017
Zug, Switzerland, September 26, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today [...]
AroCell AB: AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017
26/09/2017
AroCell AB (publ) announces today that a research poster submitted by Jagarlamudi K.K. et al. entitled" AroCell TK 210 ELISA may complement pro PSA and the prostate health index in differentiating non-cancerous from [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
26/09/2017
FIT Biotech Oy Company release September 26, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding
26/09/2017
Autolus Secures US$80 million Series C Funding Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs London, 26 September 2017 - Autolus Limited, a clinical-stage [...]
MITHRA SIGNS COMMERCIAL AGREEMENT WITH BRAZILIAN LEADER IN WOMEN'S HEALTH LIBBS FOR ESTELLE® IN BRAZIL
26/09/2017
PRESS RELEASE MIThRA SIGNS commercial agreement with Brazilian LEADER IN WOMEN's HEALTH LIBBS for Estelle® in Brazil 20-year partnership agreement expected to generate a EUR 20 million upfront milestone, as well as [...]
Nestlé details value creation plans at annual investor seminar
26/09/2017
This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, September 26, 2017 Nestlé details value creation plans at annual investor seminar Confirms mid- [...]
argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris
26/09/2017
Interim data expected in H2 2018 September 26, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]
ProLynx annonce l'octroi d'une subvention SBIR pour développer une nouvelle technologie pour les agonistes doubles de récepteurs
26/09/2017
SAN FRANCISCO, le 26 septembre 2017 (GLOBE NEWSWIRE) - ProLynx a annoncé aujourd'hui qu'elle s'est vue attribuer une subvention Small Business Innovation Research (SBIR) du NIH pour étendre sa plateforme technologique [...]
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
25/09/2017
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment. A clinically meaningful improvement of CF respiratory symptoms, as [...]
GENFIT : RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE
25/09/2017
RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE - Résultats semestriels traduisant la progression [...]
GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE
25/09/2017
2017 HALF-YEAR Results: Cash position at end of period at €126M and significant advances in the Company's pipeline - Half year results reflect the progress of elafibranor Phase 3 RESOLVE-IT study in NASH - Launch of the [...]
Sanofi : Disclosure of trading in own shares
25/09/2017
Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Sanofi : Déclaration des transactions sur actions propres
25/09/2017
Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Ossur Hf : Transactions in relation to share buyback program
25/09/2017
Announcement from Össur hf. No. 69/2017 Reykjavík, 25 September 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Ossur Hf : Össur announces efficiency initiatives
25/09/2017
Announcement no. 68/2017 Reykjavík, 25 September 2017 Össur announces efficiency initiatives At the Capital Markets Day in Copenhagen on 27 September 2017, Össur's management will elaborate on growth, innovation, and [...]
Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ)
25/09/2017
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press release Lund on September 25, 2017 Notice of [...]
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
25/09/2017
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control delivery of two or [...]
Novo Nordisk A/S - Share repurchase programme
25/09/2017
Bagsværd, Denmark, 25 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD
25/09/2017
Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT JOINS cTAP IN COLLABORATIVE EFFORT TO ENHANCE THE DEVELOPMENT OF UTROPHIN MODULATORS AND OTHER TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 25 [...]

Pages